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Boston, Massachusetts; Houston, Texas; and Rochester, MinnesotaObjectives The study objective was to validate a new high-sensitivity troponin I (hs-TnI) assay in a clinical protocol for assessing
patients who present to the emergency department with chest pain.Background Protocols using sensitive troponin assays can accelerate the rule out of acute myocardial infarction in patients with
low-risk (suspected) acute coronary syndrome (ACS).Methods This study evaluated 2 prospective cohorts of patients in the emergency department with ACS in an accelerated
diagnostic pathway integrating 0- and 2-h hs-TnI results, Thrombolysis In Myocardial Infarction (TIMI) risk scores, and
electrocardiography. Strategies to identify low-risk patients incorporated TIMI risk scores ¼ 0 or 1. The primary
endpoint was a major adverse cardiac event (MACE) within 30 days.Results In the primary cohort, 1,635 patients were recruited and had 30-day follow-up. A total of 247 patients (15.1%) had
aMACE. The ﬁnding of no ischemic electrocardiogram and hs-TnI26.2 ng/l with the TIMI¼ 0 and TIMI1 pathways,
respectively, classiﬁed 19.6% (n¼ 320) and 41.5% (n¼678) of these patients as low risk; 0% (n¼ 0) and 0.8% (n¼ 2)
had a MACE, respectively. In the secondary cohort, 909 patients were recruited. A total of 156 patients (17.2%) had
a MACE. The TIMI¼ 0 and TIMI1 pathways classiﬁed 25.3% (n ¼ 230) and 38.6% (n¼ 351), respectively, of these
patients as low risk; 0% (n ¼ 0) and 0.8% (n ¼ 1) had a MACE, respectively. Sensitivity, speciﬁcity, and negative
predictive value for TIMI ¼ 0 in the primary cohort were 100% (95% conﬁdence interval [CI]: 98.5% to 100%), 23.1%
(95% CI: 20.9% to 25.3%), and 100% (95% CI: 98.8% to 100%), respectively. Sensitivity, speciﬁcity, and negative
predictive value for TIMI 1 in the primary cohort were 99.2 (95% CI: 97.1 to 99.8), 48.7 (95% CI: 46.1 to 51.3), and
99.7 (95%CI: 98.9 to 99.9), respectively. Sensitivity, speciﬁcity, and negative value for TIMI1 in the secondary cohort
were 99.4% (95% CI: 96.5 to 100), 46.5% (95% CI: 42.9 to 50.1), and 99.7% (95% CI: 98.4 to 100), respectively.Conclusions An early-discharge strategy using an hs-TnI assay and TIMI score 1 had similar safety as previously reported, with
the potential to decrease the observation periods and admissions for approximately 40% of patients with suspected
ACS. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] Study, NCT00470587; A 2hr
Accelerated Diagnostic Protocol to Assess patients with chest Pain symptoms using contemporary Troponins as the
only biomarker [ADAPT]: a prospective observational validation study, ACTRN12611001069943) (J Am Coll
Cardiol 2013;62:1242–9) ª 2013 by the American College of Cardiology Foundation
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1243High-sensitivity troponin (hs-Tn) assays have shown
excellent diagnostic performance in the evaluation of
patients with possible acute myocardial infarction (AMI)
(1–3). However, clinicians worry that because of lower
speciﬁcity for the diagnosis of AMI (4,5), many patients
may require unnecessary investigations because of elevated
troponin values. Approximately 75% to 85% of patients who
present to emergency departments with chest pain are not
ﬁnally diagnosed with acute coronary syndrome (ACS) (6).
Prolonged assessment of these patients contributes to over-
crowding, increased costs, and adverse patient outcomes,
including increased mortality. Early-discharge strategies
combining electrocardiography (ECG), Thrombolysis In
Myocardial Infarction (TIMI) score of 0, and multimarkers
or some of the contemporary sensitive troponin assays have
classiﬁed 10% to 20% of chest pain presentations as low risk
(7,8). More patients could be safely classiﬁed as low risk by
incorporating the new hs-TnI assays into similar strategies
that assess patients with possible ACS (9).
See page 1250
Troponin testing alone cannot identify all patients at risk
for AMI or other serious cardiac conditions, and it seems
that biomarker-negative unstable angina pectoris can still be
present. Therefore, troponin testing alone is unable to iden-
tify patients who are safe for early discharge. Previous research
on hs-Tn assays has focused on their use in the early exclusion
(rule out) of AMI (1–3) but has not focused on the low-risk
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1244patients identiﬁed as low risk for serious 30-day major
adverse cardiac events (MACE).Methods
Participants. The ADP was investigated as 2 substudies;
the primary, internal cohort was ADAPT (Accelerated
Diagnostic protocol to Assess Patients with chest pain
symptoms using contemporary Troponin as the only
biomarker) (8), and the secondary external cohort was
APACE (Advantageous Predictors of Acute Coronary
Syndromes Evaluation) (3,13). In the ADAPT cohort,
patients were consecutively recruited at 2 urban emergency
departments in Brisbane, Australia, and Christchurch,
New Zealand. Patients in the ADAPT cohort were
prospectively recruited adults with at least 5 min of
possible cardiac symptoms in accordance with the Amer-
ican Heart Association case deﬁnitions (acute chest,
epigastric, neck, jaw, or arm pain; or discomfort or pressure
without a clear noncardiac source) (14). Recruitment
occurred between November 2007 and February 2011, but
local logistics resulted in different enrollment periods in
each center (8). Exclusion criteria included pregnancy,
age <18 years, unable or unwilling to consent, recruitment
inappropriate (e.g., terminal illness), transfer from another
hospital, and patients in whom follow-up was considered
impossible (e.g., homeless) (8). Data were prospectively
collected on standardized collection forms using a pub-
lished data dictionary (8,15). Research staff collected the
demographic and clinical data from patients, supervised
ECG testing, and drew blood samples for troponin testing
(8). If a patient was unsure of an answer to a question
(e.g., history of diabetes), a response of “no” was recorded
(8). In the APACE cohort, consecutive adult patients
were prospectively recruited who presented to the emergency
departments in a multinational, multicenter study with
symptoms suggestive of AMI with onset or peak symptoms
within the previous 12 h (3). Patients were excluded who had
end-stage renal failure treated with dialysis (3,13). The
ADAPT substudy was performed in accordance with details
registered with the ACTRN12611001069943 (8) and
APACE (NCT00470587) (3,13).
In both cohorts, patients received usual care according to
local hospital protocols, including blood draws for troponin
measurement at presentation and then 6 to 9 h later in
compliance with international guidelines (16) or as long as
clinically appropriate in the APACE cohort, with timing left
to the discretion of the attending physician. Additional
blood samples from consenting patients were stored for pre-
planned analysis with hs-Tn assays. In both cohorts, usual
care included further assessment by exercise tolerance
testing, nuclear myocardial perfusion scanning, coronary
computed tomography angiography, stress echocardiog-
raphy, and/or invasive coronary angiography for all patients
with elevated troponin results and/or ECG ﬁndings ofischemia. The clinical context of the presentation occa-
sionally precluded further investigation (3,8).
Patients in both studies were followed up for MACE
within 30 days using telephone follow-up and a national
health-events search (which identiﬁes any death) at least
6 months after the follow-up period. When patients reported
further medical contact in the 30-day period, their hospital
notes and documentation from subsequent medical contact
and cardiac investigations were reviewed (8). The Centre
for Clinical Research Excellence, Monash University,
Melbourne, Australia, independently undertook data co-
ordination, monitoring, and source data veriﬁcation for the
ADAPT study (8). The University Hospital, Basel,
Switzerland, undertook data coordination, monitoring, and
source data veriﬁcation for the APACE study. Approval
from local ethics committees was obtained, and all patients
had provided written informed consent.
Procedures. The primary endpoint was MACE within
30 days after initial presentation (including initial hospital
attendance). The criteria for a MACE included any of the
following: death (excluding clearly noncardiac), cardiac
arrest, AMI, emergency revascularization procedure,
cardiogenic shock, ventricular arrhythmia requiring inter-
vention, and high-degree atrioventricular block requiring
intervention.
Outcomes and investigations were reported with pre-
deﬁned, structured reporting guidelines (15). The presence
of a 30-day MACE was adjudicated independently using
these reporting guidelines. Adjudication of all cardiac
endpoints was performed by 2 cardiologists with a third
cardiologist in cases of disagreement. Cardiologists were
masked to results of the index-test biomarkers under
investigation, but they had knowledge of the clinical record,
ECG, and serial troponin results from routine care.
In accordance with international guidelines, blood was
drawn on presentation and at least 6 h later or as long as
clinically indicated for troponin results that were used to
determine the presence of myocardial necrosis (14,17).
These samples were analyzed at the recruitment site labo-
ratories (Online Appendix 1) and were the only troponin
values used in patient management. The diagnosis of AMI
was based on evidence of myocardial necrosis together with
clinical evidence of myocardial ischemia (ischemic symp-
toms, ECG changes, or imaging evidence) in accordance
with current guidelines (17). Additional details of the
criteria for adjudication are provided in Online Appendix 2.
In addition to sampling for routine clinical care, blood was
drawn on presentation and 2 h later for both the ADAPT
and APACE cohorts. Samples were immediately centri-
fuged. Serum and ethylenediaminetetraacetic plasma were
separated and stored frozen at 70C, within 2 h, for later
analysis using hs-cardiac Tn assays. During March and
April 2012 in Australia and New Zealand, and June and
September 2012 in Switzerland, previously unthawed
samples were tested with the ﬁnal pre-commercial release
Table 1
Occurrence of Major Adverse Cardiac Events During
Initial Hospital Attendance or 30-Day Follow-Up
According to Individual and Combinations of the ADP
Test Parameters in the ADAPT and APACE Cohorts
ADAPT
MACE
(n ¼ 247)
No MACE
(n ¼ 1,388)
Total
(n ¼ 1,635)
ECG*
Positive 46 (18.6) 58 (4.2) 104 (6.4)
Negative 201 (81.4)y 1,330 (95.8) 1,531 (93.6)
TIMI ¼ 0z
Positive 243 (98.4) 1,065 (76.7) 1,308 (80)
Negative 4 (1.6)y 323 (23.3) 327 (20)
TIMI 1x
Positive 210 (85.0) 693 (49.9) 903 (55.2)
Negative 37 (15.0)y 695 (50.1) 732 (44.8)
hs-TnIk
Positive 227 (91.9) 96 (6.9) 323 (19.8)
Negative 20 (8.1)y 1,292 (93.1) 1,312 (80.2)
TIMI ¼ 0 or hs-TnI or ECG{
Positive 247 (100) 1,068 (76.9) 1,315 (80.4)
Negative 0 (0)y 320 (23.1) 320 (19.6)
TIMI 1 or hs-TnI or ECG#
Positive 245 (99.2) 712 (51.3) 957 (58.5)
Negative 2 (0.8)y 676 (48.7) 678 (41.5)
APACE
MACE
(n ¼ 156)
No MACE
(n ¼ 753)
Total
(n ¼ 909)
ECG*
Positive 81 (51.9) 165 (21.9) 246 (27.1)
Negative 75 (48.1)y 588 (78.1) 663 (72.9)
TIMI ¼ 0z
Positive 155 (99.4) 504 (66.9) 659 (72.5)
Negative 1 (0.6)y 249 (33.1) 250 (27.5)
TIMI 1x
Positive 144 (92.3) 344 (45.7) 488 (53.7)
Negative 12 (7.7)y 409 (54.3) 421 (46.3)
hs-TnIjj
Positive 129 (82.7) 62 (8.2) 191 (21.0)
Negative 27 (17.3)y 691 (91.8) 718 (79.0)
TIMI ¼ 0 or hs-TnI or ECG{
Positive 156 (100) 523 (69.5) 679 (74.7)
Negative 0 (0)y 230 (30.5) 230 (25.3)
TIMI 1 or hs-TnI or ECG#
Positive 155 (99.4) 403 (53.5) 558 (61.4)
Negative 1 (0.6)y 350 (46.5) 351 (38.6)
Values are n (%). *ECG alone; any new ischemia at 0 or 2 h is positive. yNumbers of patients who
were identiﬁed as low risk by the diagnostic parameter(s) but had a MACE (i.e., false-negative
cases). zTIMI score 1 is positive. The 0-h hs-TnI result was part of the TIMI score. xTIMI
score 2 is positive. khs-TnI at 0 or 2 h >26.2 ng/l is positive. {Any new ischemia at 0 or 2 h or 0-
or 2-h hs-TnI >26.2 ng/l or TIMI 1 is positive. #Any new ischemia at 0 or 2 h or 0- or 2-h hs-TnI
>26.2 ng/l or TIMI 2 is positive.
ADP ¼ accelerated diagnostic protocol; ECG ¼ electrocardiography; hs-TnI ¼ high-sensitivity
troponin I; MACE ¼ major adverse cardiac event(s); TIMI ¼ Thrombolysis In Myocardial Infarction.
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1245version of the ARCHITECT High Sensitive STAT
Troponin-I assay (Abbott Laboratories, Abbott Park, Illinois).
Laboratory technicians were blinded to patient data.
Samples were thawed, mixed, and centrifuged (for 30 min at
3,000 relative centrifugal force and 4C for serum samples or
10 min, twice, at 3,000 relative centrifugal force for plasma
samples) before analysis and according to the manufacturer’s
instructions. The hs-TnI assay has a 99th percentile
concentration of 26.2 ng/l with a corresponding coefﬁcient
of variation of <5% and a limit of detection of 1.2 ng/l (18).
Long-term stability of TnI has been demonstrated (19).
Good correlation between plasma and serum has been
demonstrated (20). Total imprecision (coefﬁcient of varia-
tion) for the manufacturer’s quality controls measured over
11 days of specimen analysis ranged from 3.53% at 19.90
ng/l to 2.20% at 14,604 ng/l cardiac TnI (n ¼ 31 to 33) at
the Australian site.
The pre-deﬁned diagnostic protocols under investigation
included a combination of: 1) TIMI risk score; 2) ECG;
and 3) hs-TnI sampling at 0 and 2 h. The ﬁrst ADP
deﬁned low risk as patients with a TIMI score of 0 plus no
new ischemic changes on ECG and 0- and 2-h hs-TnI
concentrations 26.2 ng/l (Online Appendix 3). The second
ADP deﬁned low risk as those with a TIMI score of 1 (i.e.,
0 or 1) plus no new ischemic changes on ECG and 0- and 2-h
hs-TnI concentrations 26.2 ng/l (Online Appendix 3).
The TIMI risk score for unstable angina or non–ST-
segment elevationmyocardial infarction uses 7 predictors with
a value of 1 point assigned for each positive ﬁnding (11).
When the TIMI score was used within the ADP (Online
Appendix 3), the original criteria on ECG and biomarkers
were unnecessary because of the broader criteria required.
These 2 original TIMI parameters were incorporated within
ECG ﬁndings of new ischemic changes and increased hs-TnI
results on 0- or 2-h blood tests. Abnormal ECG criteria are
outlined in Online Appendix 4. The cutoff value for an
elevated hs-TnI was the 99th percentile (26.2 ng/l).
Statistical analysis. Baseline characteristics of the partici-
pants were calculated. For continuous variables, mean  SD
and median  interquartile range were calculated. For
categoric data, the proportions in each of the ADP-positive
and -negative groups were reported. The sensitivity, speci-
ﬁcity, and positive and negative predictive values for hier-
archical primary and secondary events were generated using
chi-square analyses for the ADP as a whole and its
constituents individually or in combination. Correlated
proportions and sensitivities were compared using the
McNemar test. Analyses were done with the Statistical
Package for the Social Sciences (version 19.0, SPSS Inc.,
Chicago, Illinois).
Results
Integrating hs-TnI with a TIMI score 1 within the
protocol classiﬁed 41.5% (678 of 1,635; p < 0.01) and
38.6% (351 of 909) of patients as low risk (ADAPT andAPACE, respectively; Table 1), while maintaining excel-
lent diagnostic statistics (Table 2). Only 0.8% and 0.6% of
the patients who had a 30-day adverse event in ADAPT
and APACE, respectively, were classiﬁed in this group.
Fewer patients were classiﬁed as low risk (19.6% [320 of
1,635] and 25.3% [230 of 909], ADAPT and APACE,
respectively) with the use of a TIMI risk score of 0 within
the ADP.
Table 2 Accuracy (95% CI) of ECG, hs-TnI, TIMI, and ADP for Exclusion of MACE
ECG* hs-TnIy TIMI ¼ 0 TIMI 1
TIMI ¼ 0 and
ECG* and hs-TnIy
TIMI 1 and
ECG* and hs-TnIy
Sensitivity ADAPT cohort 18.6 (14.3–23.9) 91.9 (87.8–94.6) 98.4 (95.9–99.4) 85.0 (80.0–88.9) 100 (98.5–100) 99.2 (97.1–99.8)
APACE cohort 51.9 (43.8–60.0) 82.7 (75.8–88.3) 99.4 (96.5–100) 92.3 (87.0–96.0) 100 (97.7–100) 99.4 (96.5–100)
Negative
predictive
value
ADAPT cohort 86.9 (85.1–88.5) 98.5 (97.7–99.0) 98.8 (96.9–99.5) 94.9 (93.1–96.3) 100 (98.8–100) 99.7 (98.9–99.9)
APACE cohort 87.7 (86.0–91.0) 96.3 (94.6–97.5) 99.6 (97.8–100) 97.2 (95.1–98.5) 100 (98.4–100) 99.7 (98.4–100)
Speciﬁcity ADAPT cohort 95.8 (94.6–96.8) 93.1 (91.6–94.3) 23.3 (21.1–25.6) 50.1 (47.4–52.7) 23.1 (20.9–25.3) 48.7 (46.1–51.3)
APACE cohort 78.1 (75.0–81.0) 91.8 (89.6–93.6) 33.1 (29.7–36.6) 54.3 (50.7–57.9) 30.5 (27.3–34.0) 46.5 (42.9–50.1)
Positive
predictive
value
ADAPT cohort 44.2 (35.1–53.8) 70.3 (65.1–75.0) 18.6 (16.6–20.8) 23.3 (20.6–26.1) 18.8 (16.8–21.0) 25.6 (22.9–28.5)
APACE cohort 32.9 (27.1–39.2) 67.5 (60.4–74.1) 23.5 (20.3–27.0) 29.5 (25.5–33.8) 23.0 (19.9–26.3) 27.8 (24.1–31.7)
*ECG alone; any new ischemia at 0 or 2 h is positive. yhs-TnI at 0 and 2 h 26.2 ng/l.
ADP ¼ accelerated diagnostic protocol; CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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1246There were 1,976 consenting patients recruited in the
ADAPT cohort, of whom 1,635 had stored samples avail-
able for the primary analysis (Fig. 1). No patients were lost to
30-day follow-up. The APACE cohort included 909
patients with stored samples for analysis (Fig. 1). Baseline
characteristics of the 2 cohorts are shown in Table 3. In the
ADAPT cohort, 247 of 1,635 patients (15.1%) had a total of
280 adverse cardiac events within 30 days of presentation;
242 events were myocardial infarction (Table 4). In the
APACE cohort, 156 of 909 patients (17.2%) had a total of
261 adverse cardiac events within 30 days of presentation;
153 events were myocardial infarction. Contribution of the
individual parameters of the ADP and combinations of these
are shown in Online Appendix 5.
In the ADAPT and APACE cohorts, 94.9% and 96.0% of
patients, respectively, had an hs-TnI value on presentation
above the limit of detection (1.2 ng/l) for the hs-TnI assay
(Table 5).Figure 1 ADAPT and APACE Cohort-Participant Flow Diagrams for th
Shown are the ADAPT (Accelerated Diagnostic protocol to Assess Patients with chest Pa
(Advantageous Predictors of Acute Coronary Syndromes Evaluation) (right) ﬂow diagrams
sensitivity troponin T; MACE ¼ major adverse cardiac event(s); TIMI ¼ Thrombolysis In MFurther objective investigations within the 30-day period,
including exercise stress testing, echocardiography, computed
tomography coronary angiography, and angiography, were
performed in 246 patients (76.9 %) and 519 patients (76.5%)
in the ADAPT low-risk cohorts analyzed using TIMI ¼
0 and TIMI1, respectively, and 51 patients (22.2 %) and 94
patients (26.8%) in the APACE low-risk cohort analyzed
using TIMI ¼ 0 and TIMI 1, respectively (Table 3).
Two patients in the ADAPT cohort and 1 patient in the
APACE cohort were determined as low risk and had a 30-
day event (Online Appendix 6). The adjudicated diagnosis
for all 3 of these patients was non–ST-segment myocardial
infarction.Discussion
Two large, international, multicentered emergency depart-
ment cohorts have validated the integration of hs-TnIe Accelerated Diagnostic Protocol Incorporating hs-TnI and TIMI 1
in symptoms using contemporary troponin as the only biomarker) (left) and APACE
. ADP ¼ accelerated diagnostic protocol; ECG ¼ electrocardiogram; hs-TnT ¼ high-
yocardial Infarction.
Table 3 Characteristics for Low-Risk and High-Risk Participants in the ADAPT and APACE Cohorts
Characteristics
ADAPT Cohort (n ¼ 1,635) APACE Cohort (n ¼ 909)
Low Risk
(TIMI 1, Normal ECG
and Normal hs-TnI)
(n ¼ 678)
High Risk
(TIMI >1 or Abnormal ECG
or Increased hs-TnI)
(n ¼ 957)
Low Risk
(TIMI 1, Normal ECG
and Normal hs-TnI)
(n ¼ 351)
High Risk
(TIMI >1 or Abnormal ECG
or Increased hs-TnI)
(n ¼ 558)
Age, yrs 51.3 (11.9) 67.0 (13.5) 53.5 (14.6) 66.4 (13.8)
Male, % 399 (58.8) 577 (60.3) 238 (67.8) 397 (71.1)
Risk factors
Hypertension 197 (29.1) 655 (68.4) 139 (39.6) 437 (78.3)
Dyslipidemia 236 (34.8) 689 (72) 72 (20.5) 345 (61.8)
Diabetes 40 (5.9) 203 (21.2) 26 (7.4) 131 (23.5)
Family history of coronary artery disease 312 (46) 617 (64.5) 58 (16.5) 142 (25.4)
Smoking (current) 156 (23) 143 (14.9) 124 (35.3) 111 (19.9)
Medical history
Angina 46 (6.8) 543 (56.7) Not recorded Not recorded
AMI 6 (0.9) 380 (39.7) 3 (0.9) 215 (38.5)
Angiography 2 (0.3) 282 (29.5) 3 (0.9) 230 (41.2)
Congestive heart failure 6 (0.9) 120 (12.5) 17 (4.8) 96 (17.2)
Cerebrovascular event 29 (4.3) 154 (16.1) 8 (2.3) 37 (6.6)
CABG 1 (0.1) 138 (14.4) 1 (0.3) 83 (14.9)
Time of symptom onset to presentation (h)
Mean (SD) 21.1  58.5 23.4  62.5 13.5  21.9 14.1  21.4
Median (IQR) 4.6 (1.7–14.9) 6.2 (2.4–16.6) 4 (2–11) 5 (3–12)
Length of initial hospital attendance (h)
Mean (SD) 39.7  59.6 104.4  151.5 29.7  65.9 115.8  200.0
Median (IQR) 26.3 (10.4–31.4) 65.9 (28.5–124.8) 7.2 (5–21.8) 47.9 (8.2–169.2)
Investigations within 30 days
Stress ECG 446 (65.8) 206 (21.5) 64 (18.2) 76 (13.6)
Stress radionuclide imaging 42 (6.2) 50 (5.2) 22 (6.3) 80 (14.3)
Stress echocardiogram 8 (1.2) 20 (2.1) Not recorded Not recorded
Non-stress echocardiogram 48 (7.1) 130 (13.6) Not recorded Not recorded
Angiography 57 (8.4) 317 (33.1) 12 (3.4) 194 (34.8)
Values are n (%) except for age, time of symptom onset, and length of initial hospital attendance. Data were missing for time of symptom onset to presentation (7 in ADAPT and 12 in APACE). Length of
hospital attendance was 59h in ADAPT and 29h in APACE.
ADP ¼ accelerated diagnostic protocol; AMI ¼ acute myocardial infarction; ADAPT ¼ Accelerated Diagnostic protocol to Assess Patients with chest Pain symptoms using contemporary troponin as the only
biomarker; APACE ¼ Advantageous Predictors of Acute Coronary Syndromes Evaluation; CABG ¼ coronary artery bypass grafting; other abbreviations as in Table 1.
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1247results in a 2-h investigative pathway for the assessment of
patients with possible ACS. The strategy using TIMI ¼
0 classiﬁed similar numbers of patients as low risk as
previously reported using currently available troponin assays
(8,21), while maintaining a sensitivity of >99% in both
cohorts. The strategy incorporating a TIMI risk score 1
doubled the proportion of patients in the emergency
department who are classiﬁed as low risk while maintaining
>99% sensitivity and negative predictive value for adverse
events in both cohorts. This ﬁnding suggests that approx-
imately 40% of patients presenting to emergency depart-
ments with possible cardiac chest pain could rapidly and
safely progress to early discharge for outpatient manage-
ment (22). The increase in the proportion of patients
identiﬁed as low risk incorporating TIMI 1 in the
strategy has the potential to have a considerable impact on
reducing hospital admission rates and emergency depart-
ment overcrowding.
Incorporating hs-TnI results in clinical practice pathways
will improve the management of patients presenting with
chest pain to emergency departments. The strategyintegrating hs-TnI with TIMI 1 resulted in an improved
speciﬁcity of >45% for risk of 30-day cardiac events. This
ﬁnding is in contrast to previous studies that have found that
the improvements in analytic performance of hs-Tn assays
have led to increased rates of elevated troponin and
decreased speciﬁcity for AMI (4).
This is the ﬁrst paper to validate the clinical integration of
hs-TnI into a pragmatic and useful algorithm for medical
decision-making in real-life practice. Until now, there has
been no literature to provide guidance on how to use hs-TnI
in clinical care. Guideline bodies have recommended that
the 99th percentile (and not other cutoff levels) be used in
clinical practice irrespective of the troponin assay (23,24).
This study demonstrates the effectiveness of this cutoff value
in combination with the TIMI risk score and ECG ﬁndings
in clinically useful algorithms for patients with possible
ACS in the emergency department.
Some techniques optimize the use of hs-Tn assays using
alternative cutoff values (other than the 99th percentile) and
change metrics (deltas) (1,2). The details of these techniques
need to be individualized for each new assay (10). The value
Table 4
Frequency of Major Adverse Cardiac Events During
Initial Hospital Attendance or 30-Day Follow-Up Period
in the ADAPT and APACE Cohorts
ADAPT Cohort*
(n ¼ 1,635)
APACE Cohorty
(n ¼ 909)
No. of
Events
Frequency of
Event Type (%)
No. of
Events
Frequency of
Event Type (%)
NSTEMI 225 13.8 142 15.6
Emergency
revascularization
19 1.2 83z 9.1z
STEMI 17 1.0 11 1.2
Cardiovascular death 5 0.3 11 1.2
Ventricular arrhythmia 5 0.3 3 0.3
High atrioventricular
block
5 0.3 7 0.8
Cardiogenic shock 3 0.2 2 0.2
Cardiac arrest 1 0.1 2 0.2
*A total of 247 of 1,635 patients (15.1%) in the ADAPT cohort had 280 events. yA total of 156 of
909 patients (17.2%) in the APACE cohort had 261 events. zRevascularization within 24 h.
ADAPT ¼ Accelerated Diagnostic protocol to Assess Patients with chest Pain symptoms using
contemporary troponin as the only biomarker; APACE¼ Advantageous Predictors of Acute Coronary
Syndromes Evaluation; NSTEMI ¼ non–ST-segment myocardial infarction; STEMI ¼ ST-segment
elevation myocardial infarction (occurring after initial recruitment).
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1248of serial changes (deltas) was not assessed in this study. The
limit of detection for hs-TnT has been suggested to be
clinically useful as a cutoff value. An unrecordable hs-TnT
value was found in up to 30% of patients on initial
presentation, supporting this cutoff value for the early rule
out of AMI when using this assay (1). We cannot recom-
mend the use of the limit of detection as a cutoff value for
this assay because of the improved ability of hs-TnI assays to
detect troponin concentrations in the normal range, sup-
ported by our ﬁnding that the majority of patients (>95%)
had deﬁned troponin values on presentation.
Three patients in the low-risk group were diagnosed with
30-day events. It is possible that these were cases of false-
negative results with hs-TnI (25). However, it is also
possible that the apparent troponin elevation identiﬁed with
the troponin assay in clinical use at the time of recruitment
may have been a false-positive result, and the adjudicated
outcomes were incorrect (26) (Online Appendix 6).
Study limitations. The applicability of this risk-stratiﬁcation
process is limited to patients with chest pain or discomfort.
Patients with ACS and other serious conditions may present
with atypical symptoms, such as fatigue or nausea without
associated chest discomfort. Most patients recruited were
Caucasian, limiting the generalizability of the results to other
populations; however, the studies were conducted in 2Table 5
Participants With Detectable Troponin Values
(>1.2 ng/l) on Presentation
n %
ADAPT cohort 1,551 94.9
APACE cohort 873 96.0
ADAPT ¼ Accelerated Diagnostic protocol to Assess Patients with chest Pain symptoms using
contemporary troponin as the only biomarker; APACE¼ Advantageous Predictors of Acute Coronary
Syndromes Evaluation.geographically distinct regions. During these observational
studies, at least 77% of patients in the ADAPT and 27% of
patients in the APACE low-risk cohorts received further
treatment and/or investigations during the index presentation.
In low-risk patients, we would argue such studies can be safely
accomplished on an outpatient basis (27,28), but further
studies (ideally in a randomized controlled trial) are required to
determine whether further investigation (including outpatient
testing) is required in the low-risk cohort to prevent longer-
term, adverse outcomes.
Conclusions
An early-discharge strategy using an hs-TnI assay and TIMI
score 1 had similar safety as previously reported, with the
potential to decrease the observation periods and admissions
for approximately 40% of patients with suspected ACS.
Acknowledgments
The authors thank the patients who participated in the
study, the research staff, the emergency department staff,
and the laboratory technicians of all participating sites for
valuable efforts.
Reprint requests and correspondence: Dr. Louise Cullen,
Department of Emergency Medicine, Royal Brisbane andWomen’s
Hospital, Herston, Brisbane, Queensland, Australia 4029. E-mail:
louise_cullen@health.qld.gov.au.REFERENCES
1. Body R, Carley S, McDowell G, et al. Rapid exclusion of acute
myocardial infarction in patients with undetectable troponin using
a high-sensitivity assay. J Am Coll Cardiol 2011;58:1332–9.
2. Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive
troponin I assay and early diagnosis of myocardial infarction. JAMA
2011;306:2684–93.
3. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of
myocardial infarction with sensitive cardiac troponin assays. N Engl J
Med 2009;361:858–67.
4. Jairam S, Jones P, Samaraie L, Chataline A, Davidson J, Stewart R.
Clinical diagnosis and outcomes for Troponin T ‘positive’ patients
assessed by a high sensitivity compared with a 4th generation assay.
Emerg Med Australas 2011;23:490–501.
5. De Lemos JA, Morrow DA, de Filippi CR. Highly sensitive troponin
assays and the cardiology community: a love/hate relationship? Clin
Chem 2011;57:826–9.
6. Chase M, Robey J, Zogby K, Sease K, Shofer F, Hollander J.
Prospective validation of the Thrombolysis in Myocardial Infarction
risk score in the emergency department chest pain population. Ann
Emerg Med 2006;48:252–9.
7. Than M, Cullen L, Reid CM, et al. A 2-h diagnostic protocol to assess
patients with chest pain symptoms in the Asia-Paciﬁc region
(ASPECT): a prospective observational validation study. Lancet 2011;
377:1077–84.
8. Than M, Cullen L, Aldous S, et al. 2-hour accelerated diagnostic
protocol to assess patients with chest pain symptoms using contem-
porary troponins as the only biomarker: the ADAPT Trial. J Am Coll
Cardiol 2012;59:2091–8.
9. Twerenbold R, Jaffe A, Reichlin T, Reiter M, Mueller C. High-
sensitive troponin T measurements: what do we gain and what are the
challenges? Eur Heart J 2012;33:579–86.
10. Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity
cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252–7.
JACC Vol. 62, No. 14, 2013 Cullen et al.
October 1, 2013:1242–9 hs-Troponin I Strategy for Chest Pain
124911. Antman EM. The TIMI risk score for unstable angina/non-ST
elevation MI: a method for prognostication and therapeutic decision
making. JAMA 2000;284:835–42.
12. Goodacre SW, Bradburn M, Cross E, et al. The Randomised
Assessment of Treatment using Panel Assay of Cardiac Markers
(RATPAC) trial: a randomised controlled trial of point-of-care cardiac
markers in the emergency department. Heart 2011;97:190–6.
13. Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and
relative changes in cardiac troponin concentrations in the early diag-
nosis of acute myocardial infarction. Circulation 2011;124:136–45.
14. Luepker RV, Apple FS, Christenson RH, et al. Case deﬁnitions for
acute coronary heart disease in epidemiology and clinical research
studies: a statement from the AHA Council on Epidemiology and
Prevention; AHA Statistics Committee; World Heart Federation
Council on Epidemiology and Prevention; the European Society of
Cardiology Working Group on Epidemiology and Prevention; Centers
for Disease Control and Prevention; and the National Heart, Lung,
and Blood Institute. Circulation 2003;108:2543–9.
15. Cullen L, Than M, Brown AF, et al. Comprehensive standardized data
deﬁnitions for acute coronary syndrome research in emergency
departments in Australasia. Emerg Med Australas 2010;22:35–55.
16. Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk
patients presenting to the emergency department with chest pain:
a scientiﬁc statement from the American Heart Association. Circula-
tion 2010;122:1756–76.
17. Thygesen K, Alpert JS, White HD, et al. Universal deﬁnition of
myocardial infarction. Circulation 2007;116:2634–53.
18. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity
cardiac troponin assays. Clin Chem 2012;58:54–61.
19. Kavsak PA, MacRae AR, Yerna MJ, Jaffe AS. Analytic and clinical
utility of a next-generation, highly sensitive cardiac troponin I assay for
early detection of myocardial injury. Clin Chem 2009;55:573–7.
20. Koerbin G, Tate J, Potter JM, Cavanaugh J, Glasgow N,
Hickman PE. Characterisation of a highly sensitive troponin I assay
and its application to a cardio-healthy population. Clin Chem Lab
Med 2012;50:871–8.21. Aldous SJ, Richards MA, Cullen L, Troughton R, Than M. A new
improved accelerated diagnostic protocol safely identiﬁes low-risk
patients with chest pain in the emergency department. Acad Emerg
Med 2012;19:510–6.
22. Scheuermeyer FX, Christenson J, Innes G, Boychuk B, Yu E,
Grafstein E. Safety of assessment of patients with potential ischemic
chest pain in an emergency department waiting room: a prospective
comparative cohort study. Ann Emerg Med 2010;56:455–62.
23. Thygesen K, Alpert JS, White HD, et al. Universal deﬁnition of
myocardial infarction. Circulation 2007;116:2634–53.
24. Thygesen K, Mair J, Giannitsis E, et al. How to use high-
sensitivity cardiac troponins in acute cardiac care. Eur Heart J
2012;33:2252–7.
25. Eriksson S, Halenius H, Pulkki K, Hellman J, Pettersson K. Negative
interference in cardiac troponin I immunoassays by circulating troponin
autoantibodies. Clin Chem 2005;51:839–47.
26. Panteghini M. A critical appraisal of experimental factors inﬂuencing
the deﬁnition of the 99th percentile limit for cardiac troponins. Clin
Chem Lab Med 2009;47:1179–82.
27. Meune C, Reichlin T, Irfan A, et al. How safe is the outpatient
management of patients with acute chest pain and mildly increased
cardiac troponin concentrations? Clin Chem 2012;58:916–24.
28. Meyer MC, Mooney RP, Sekera AK. A critical pathway for patients
with acute chest pain and low risk for short-term adverse cardiac
events: role of outpatient stress testing. Ann Emerg Med 2006;47:
435.e1–3.Key Words: acute myocardial infarction - ADAPT - APACE -
chest pain - high-sensitivity troponin I - TIMI.
APPENDIX
For supplemental information, please see the online version of this article.
